Lv31
360 积分 2024-12-10 加入
Efficacy of immune checkpoint inhibitors in the first line therapy of non-squamous non-small cell lung cancer: A systematic review and network meta-analysis
1小时前
已完结
Cost-effectiveness analysis of radiotherapy versus surgery for esophageal squamous cell carcinoma in China: a Markov model study based on real-world data
7天前
已完结
Bayesian Indirect Comparison and Cost-Effectiveness of Sacituzumab Govitecan Versus Sacituzumab Tirumotecan in Metastatic Triple-Negative Breast Cancer
13天前
已完结
Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer
13天前
已完结
Comparative cost-effectiveness of sintilimab, toripalimab, and camrelizumab in first-line therapy for advanced non-squamous non-small cell lung cancer
13天前
已完结
A Comparison of Different Approaches for Costing Medication Use in an Economic Evaluation
1个月前
已完结
Adverse Event Costs and Cost-Effectiveness Analyses of Anticancer Drugs
2个月前
已完结
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis
2个月前
已完结
Systematic review of cost-effectiveness of Chinese PD-1/PD-L1 inhibitors as first-line treatment for hepatocellular carcinoma
3个月前
已完结
Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer
3个月前
已完结
皖公网安备34019202002308
